AQEMIA
28.6.2024 07:31:26 CEST | Business Wire | Press release
AQEMIA, a leading company in generative-AI-driven drug discovery, announces the achievement of a research milestone in its collaboration with Servier, an international independent pharmaceutical company, to address an undruggable target in immuno-oncology.
Based on AQEMIA ‘s quantum and statistical physics-based calculations, and within the span of a few months, a series of molecules experimentally active on an undruggable target in immuno-oncology have been successfully identified. This milestone triggers an undisclosed payment to AQEMIA.
"Our teams are very proud of this achievement that demonstrates the power of AQEMIA's cutting-edge generative AI and deep physics in creating novel, patentable molecules to meet therapeutic needs that are still immense, particularly in the field of immuno-oncology. Within the framework of our collaboration with Servier, we have reached the stage where a series of molecules are subsequently proven impactful in vitro and in vivo assays. " said Maximilien Levesque, PhD, CEO and Co-founder of AQEMIA.
This critical milestone is a continuation of Servier and AQEMIA’s successful partnership program, initiated in December 2021, to accelerate drug candidate discovery in immuno-oncology using artificial intelligence and deep physics.
AQEMIA has worked on more than a dozen in-house therapeutic programs in oncology and immuno-oncology, as well as in new therapeutic areas such as immunology, inflammation and diseases of the central nervous system. To date, AQEMIA’s three most advanced programs are being tested against cancers in animals.
About AQEMIA
AQEMIA is a next-gen techbio generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast many innovative drug candidates for critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms to power a generative artificial intelligence designing novel drug candidates, without the need to train on experimental data. We already delivered several drug discovery successes in internal pipeline as well as in collaboration with Pharma companies - most advanced programs being currently in vivo optimization.
For more information, visit AQEMIA.com and our LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627468833/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Collaborates with Synopsys to Provide Simulation Models Through Ansys Electromagnetic and Thermal Analysis Tools16.6.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) announces a new collaboration with Synopsys, Inc., enabling users of Synopsys' simulation tools to navigate directly to Murata's website to access and download the latest high-performance simulation models from Murata. The collaboration covers Synopsys' 3D electromagnetic field analysis tool Ansys HFSS™ and thermal analysis tool Ansys Icepak®, and marks a significant step toward streamlining the simulation workflow for electronic circuit designers. Murata is also the first company to offer passive component simulation models via Ansys Icepak*. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615241645/en/ [Murata Manufacturing Co., Ltd.] New collaboration with Synopsys As demand for high-speed, high-capacity communications continues to grow, electronic circuit design has become increasingly complex. Engineers must now account for a range of physical phenomena
Trimontium Launches with $1.5 billion in AUM, Redefining Flexible CapitalSolutions16.6.2026 01:01:00 CEST | Press release
Founded by former Blackstone executive Vlado Spasov, Trimontium is an institutionally backed alternative asset manager purpose-built to deliver flexible capital solutions across Europe and North America Trimontium (the “Firm”), an institutionally backed alternative asset manager specialising in flexible capital solutions, today announced its launch with $1.5 billion in assets under management. The Firm’s investment approach is rooted in credit and special-situations expertise, with the flexibility to originate and execute tailored financing solutions across the full capital structure for a wide range of corporate needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615892895/en/ Trimontium Founder and CIO, Vlado Spasov Founded by former Blackstone executive Vlado Spasov, Trimontium is one of the largest first-time alternative asset managers based in Europe focused on flexible capital solutions to launch, according to ava
Newmont Announces Key Executive Appointments for the Next Phase of Delivery15.6.2026 23:20:00 CEST | Press release
Newmont Corporation (NYSE: NEM, ASX: NEM, PNGX: NEM) (“Newmont”) today announced leadership appointments that further shape its go-forward Executive Leadership Team under President and Chief Executive Officer Natascha Viljoen and reflect the depth of leadership talent within the company. Effective July 1, 2026, Brian Tabolt has been appointed Chief Financial Officer, Mark Rodgers has been appointed Chief Operating Officer, and David Thornton has been appointed Chief Technical Officer. In addition, David Fry has been promoted to Executive Vice President, Project Development, reflecting the importance of disciplined project development and execution as Newmont advances its highest-return growth opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615487768/en/ Mark Rodgers - COO “These appointments bring together respected leaders with deep industry experience and a strong understanding of our operational, financia
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom